Eli Lilly and Co. will gain full ownership of the impotence treatment Cialis with a $2.1 billion acquisition of joint venture partner Icos Corp., the companies announced Tuesday. Lilly will pay $32 ...

Icos Corp., the largest publicly traded biotechnology company in the Seattle area and the developer of the erectile dysfunction drug Cialis, has agreed to be acquired for $2.1 billion in cash by its ...

Eli Lilly & Co. bumped up its offer for Bothell's Icos Corp. on Monday by 6 percent after a proxy firm and others advised shareholders to vote against an earlier offer. Lilly originally offered $32 ...

Eli Lilly has agreed to purchase ICOS, co-marketer of erectile dysfunction drug Cialis (tadalfil), for approximately $2.1 billion. Lilly and ICOS have been partners in Cialis since 1998 and launched ...